Cue Biopharma Files 8-K on Material Agreement

Ticker: CUE · Form: 8-K · Filed: Apr 15, 2025 · CIK: 1645460

Sentiment: neutral

Topics: material-agreement, 8-k, financial-reporting

TL;DR

Cue Biopharma signed a big deal, filing an 8-K on 4/14/25.

AI Summary

On April 14, 2025, Cue Biopharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers results of operations and financial condition, along with other events and financial statements. The company, formerly known as Imagen Biopharma, Inc., is incorporated in Delaware and headquartered in Boston, Massachusetts.

Why It Matters

This 8-K filing indicates Cue Biopharma has entered into a significant agreement, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement Cue Biopharma entered into?

The filing states an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on April 14, 2025.

What was Cue Biopharma's former company name?

Cue Biopharma, Inc.'s former company name was Imagen Biopharma, Inc.

Where are Cue Biopharma's principal executive offices located?

Cue Biopharma's principal executive offices are located at 40 Guest Street, Boston, Massachusetts, 02135.

What is the SIC code for Cue Biopharma, Inc.?

The Standard Industrial Classification (SIC) code for Cue Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 15, 2025 regarding Cue Biopharma, Inc. (CUE).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing